New drug offers hope for treating Huntington's disease

Researchers at UCL fix a protein defect that causes devastating genetic disease Huntington's in patients for first time.

    Huntington's disease causes irreversible damage to the brain [File: Reuters]
    Huntington's disease causes irreversible damage to the brain [File: Reuters]

    An experimental drug has for the first time been shown to slow the progression of Huntington's disease, giving hopes to patients suffering from the incurable disorder.

    Scientists at UK's University College of London said on Monday that an early-stage trial found that the treatment had "successfully lowered" the levels of a toxic protein that causes the devastating genetic disease.

    Sarah Tabrizi, a professor of clinical neurology who led the UCL research, called the ability of the drug, IONIS-HTT(Rx), to lower the mutant huntingtin protein "ground-breaking".

    "The key now is to move quickly to a larger trial to test whether IONIS-HTT(Rx) slows disease progression," she said. 

    The Huntington's Disease Society of America hailed the breakthrough as "a historic moment in the fight against" the illness.  

    What is Huntington's disease?

    Huntington's is a disorder that causes irreversible damage to the brain, affecting patients' movements, behaviour and ability to think clearly.

    It is caused by an inherited defect in a single section of DNA called the huntingtin gene.

    Most people with Huntington's develop symptoms in their early 30s or 40s and die around 10 to 20 years after symptoms start.

    There is currently no treatment to stop or reverse the disease, and existing medication can only help manage its symptoms.

    Landmark trial

    The UCL trial involved 46 patients from the UK, Germany and Canada.

    They were each given four spinal injections of either the drug or a placebo. 

    UCL said the drug produced "significant, dose-dependent lowering of the level of mutant huntingtin" and marks the first time that the protein has been reduced in the nervous systems of patients.

    IONIS-HTT(Rx) works by effectively silencing the defective huntingtin gene. 

    Professor John Hardy, an expert on diseases affecting the nervous system, told the BBC that the trial was "potentially, the biggest breakthrough in neurodegenerative disease in the past 50 years". 

    Ionis Pharmaceuticals, the company behind the drug, said in a statement on Monday that, following the trial, pharmaceutical giant Roche had exercised its right to license IONIS-HTT(Rx) at a cost of $45m.

    The prevalence of the disease varies by ethnicity and geographical location. In Europe, it is estimated that about five to seven people in 100,000 are affected.

    About 8,500 people in the UK have Huntington's, while 30,000 people have it in the United States.

    SOURCE: Al Jazeera News


    YOU MIGHT ALSO LIKE

    Interactive: How does your country vote at the UN?

    Interactive: How does your country vote at the UN?

    Explore how your country voted on global issues since 1946, as the world gears up for the 74th UN General Assembly.

    'We were forced out by the government soldiers'

    'We were forced out by the government soldiers'

    We dialled more than 35,000 random phone numbers to paint an accurate picture of displacement across South Sudan.

    Interactive: Plundering Cambodia's forests

    Interactive: Plundering Cambodia's forests

    Meet the man on a mission to take down Cambodia's timber tycoons and expose a rampant illegal cross-border trade.